Physician profile
John Brian Reed
NPI 1528177706
$1,961.43
in general payments reported to CMS, 2019-2025
16 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $256 · 2021: $115 · 2022: $90.03 · 2023: $398 · 2024: $425 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $371.80 | 2023-2025 | Acthar |
| Genentech USA, INC. | $346.44 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $248.85 | 2019-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $230.95 | 2019-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $140.50 | 2020 | |
| Apellis Pharmaceuticals, INC. | $116.68 | 2023-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $110.36 | 2025 | Purified Cortrophin Gel, Iluvien |
| Novartis Pharmaceuticals Corporation | $92.66 | 2019-2021 | |
| Neurotech Pharmaceuticals, INC. | $87.72 | 2025 | |
| Eyepoint US, INC. | $46.86 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $43.75 | 2023 | Xipere, Visudyne, Retisert |
| Astellas Pharma US INC | $31.31 | 2023 | |
| Amgen INC. | $29.25 | 2024-2025 | Pavblu |
| Biogen, INC. | $24.99 | 2024 | Byooviz |
| Horizon Therapeutics Plc | $20.38 | 2023 | Tepezza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.